Curiox Biosystems Co., Ltd (KOSDAQ:445680)
South Korea · Delayed Price · Currency is KRW 110,400
+8,500 (8.34%)
At close: Dec 29, 2025
Curiox Biosystems Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4,258 | 4,588 | 6,788 | 7,237 | 5,523 | 4,384 |
Other Revenue | - | - | - | -0 | - | - |
| 4,258 | 4,588 | 6,788 | 7,237 | 5,523 | 4,384 | |
Revenue Growth (YoY) | -28.63% | -32.41% | -6.21% | 31.04% | 25.97% | - |
Cost of Revenue | 2,502 | 2,029 | 2,963 | 2,504 | 2,029 | 1,454 |
Gross Profit | 1,756 | 2,559 | 3,825 | 4,733 | 3,494 | 2,930 |
Selling, General & Admin | 10,423 | 11,654 | 10,626 | 13,217 | 10,129 | 4,930 |
Research & Development | 2,811 | 2,504 | 2,109 | 1,470 | 459.64 | 172.31 |
Amortization of Goodwill & Intangibles | 1,190 | 1,134 | 1,081 | 1,041 | 946.51 | 950.56 |
Other Operating Expenses | - | - | - | 41.27 | 23.69 | 17.49 |
Operating Expenses | 15,046 | 15,937 | 14,382 | 16,154 | 11,831 | 6,197 |
Operating Income | -13,291 | -13,378 | -10,557 | -11,421 | -8,337 | -3,267 |
Interest Expense | -1,489 | -702.03 | -25.7 | -2,777 | -1,704 | -1,390 |
Interest & Investment Income | 623.51 | 549.58 | 236.06 | 162.94 | 28.59 | 43.57 |
Currency Exchange Gain (Loss) | 804.62 | 1,433 | 117.78 | 42.83 | 338.5 | -311.99 |
Other Non Operating Income (Expenses) | -9,415 | 4,225 | 4.93 | 2,714 | -4,935 | -1,503 |
EBT Excluding Unusual Items | -22,767 | -7,873 | -10,224 | -11,278 | -14,609 | -6,428 |
Gain (Loss) on Sale of Assets | -115.44 | -123.27 | 13.02 | -12.11 | - | - |
Asset Writedown | -479.78 | - | - | - | -84.1 | - |
Pretax Income | -23,362 | -7,996 | -10,211 | -11,290 | -14,693 | -6,428 |
Income Tax Expense | -114.31 | 93.67 | -169.26 | 207.32 | -167.52 | -148.84 |
Earnings From Continuing Operations | -23,247 | -8,089 | -10,042 | -11,498 | -14,525 | -6,279 |
Minority Interest in Earnings | 0.35 | 0.47 | 1.28 | 3 | 1.31 | -0.13 |
Net Income | -23,247 | -8,089 | -10,040 | -11,495 | -14,524 | -6,279 |
Net Income to Common | -23,247 | -8,089 | -10,040 | -11,495 | -14,524 | -6,279 |
Shares Outstanding (Basic) | 16 | 16 | 14 | 7 | 13 | 13 |
Shares Outstanding (Diluted) | 16 | 16 | 14 | 7 | 13 | 13 |
Shares Change (YoY) | 1.26% | 15.26% | 101.43% | -45.55% | - | - |
EPS (Basic) | -1429.44 | -503.42 | -702.41 | -1619.76 | -1114.48 | -481.84 |
EPS (Diluted) | -1647.26 | -706.00 | -702.41 | -1619.76 | -1114.50 | -481.84 |
Free Cash Flow | -10,366 | -9,956 | -8,376 | -10,711 | -5,387 | -2,849 |
Free Cash Flow Per Share | -637.41 | -604.30 | -585.95 | -1509.32 | -413.36 | -218.63 |
Gross Margin | 41.24% | 55.77% | 56.35% | 65.40% | 63.27% | 66.83% |
Operating Margin | -312.12% | -291.61% | -155.53% | -157.81% | -150.95% | -74.52% |
Profit Margin | -545.94% | -176.32% | -147.92% | -158.83% | -262.98% | -143.22% |
Free Cash Flow Margin | -243.44% | -217.02% | -123.39% | -148.00% | -97.54% | -64.99% |
EBITDA | -10,621 | -10,800 | -8,605 | -9,823 | -7,101 | -2,147 |
EBITDA Margin | -249.42% | -235.41% | -126.77% | -135.73% | -128.58% | -48.98% |
D&A For EBITDA | 2,670 | 2,578 | 1,952 | 1,598 | 1,236 | 1,120 |
EBIT | -13,291 | -13,378 | -10,557 | -11,421 | -8,337 | -3,267 |
EBIT Margin | - | -291.61% | -155.53% | -157.81% | -150.95% | -74.52% |
Advertising Expenses | - | 544.76 | 775.87 | 939.61 | 397.57 | 129.69 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.